5 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds

Page 1 of 5

In this article, we will list the 5 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds. Please visit 7 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds if you’d like to see an extended list and the methodology behind it.

5. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD)

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds.

On February 26, Citizens analyst Jason Butler maintained an Outperform rating on Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD). The firm increased its price target from $8 to $10. Citizens noted that the company’s fourth-quarter results were in line with guidance and highlighted the reaffirmed 2026 outlook, including adjusted EBITDA of over $300M.

It added that LINZESS-related headwinds appear to have eased, positioning the company to generate meaningful cash flow to support debt obligations and fund future growth initiatives.

On February 25, Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) announced guidance for fiscal year 2026 adjusted EBITDA to be at least $300 million. The company stated that it is focused on maximizing LINZESS and advancing apraglutide while also sustaining profits and cash flows.

In 2026, the company expects higher net sales for LIZNESS in the U.S. and expects a disciplined approach towards expense control to generate more than $300 million in adjusted EBITDA, which will consequently support the continued development of apraglutide and will enable debt reduction to further enhance the company’s financial strength.

The company also sees apraglutide as an opportunity to redefine the standard of how patients receive care with SBS-IF, and is looking forward to the initiation of sites for the confirmatory Phase 3 clinical trial called STARS-2 in the second quarter of this year.

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is involved in the development and commercialization of therapeutics for gastrointestinal (GI) and rare diseases. It also sells linaclotide under the brand names LINZESS and CONSTELLA. Additionally, it is also working on the development of IW-3300 and Apraglutide.

Page 1 of 5